NCT02187562已完成1 期
Effect of Steady State Meloxicam 15 mg/Day on Low Dose Aspirin (100 mg/Day) Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females. An Open, Randomised, Two-way Crossover Study.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- Arachidonic acid induced platelet aggregation
研究概览
简要总结
The objective of this study was to investigate the influence of meloxicam on low dose aspirin induced inhibition of platelet aggregation and thromboxane B2, when meloxicam is given before aspirin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female subjects as determined by results of screening
- •Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- •Age >=18 and <= 60 years
- •The Body Mass Index (BMI) ≥ 18.5 kg/m2 (square meters) and ≤ 29.9 kg/m
- •Laboratory values within a clinical normal range
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastro-intestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
- •Use of any drugs, which might influence the results of the trial, in particular aspirin containing drugs(< 14 days prior to administration or during the trial)
- •Participation in another trial with an investigational drug (< 1 months prior to administration (at least 10 times the relevant elimination half-life) or during trial)
- •Having had prescription medication 2 weeks prior to study drug administration or over the counter medication 1 week prior to study drug administration (at least 10 times the relevant elimination half-life)
- •Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (> 60 grams (g)/day)
- •Drug abuse
- •Blood donation or loss > 400 mL (< 1 month prior to administration or during the trial)
- •Excessive physical activities (< 5 days prior to administration or during the trial)
- •Any ECG value outside of the reference range of clinical relevance including, but not limited to QTcB > 480 ms or QRS interval > 110 ms
- •History of any familial bleeding disorder
- •History of haemorrhagic diatheses
- •History of gastrointestinal ulcer, perforation or bleeding
- •History of bronchial asthma
- •Inability to comply with dietary regimen of study centre
- •Inability to comply with investigator's instructions
- •For female subjects:
- •Pregnancy
- •Positive pregnancy test
- •No adequate contraception (e.g. sterilisation, intrauterine device (IUP), oral contraceptives)
- •Inability to maintain this adequate contraception during the whole study period
- •Lactation period
- •Ovarian hormone substitution and oral contraception have to be continued during the study
研究组 & 干预措施
Meloxicam/Aspirin
Experimental
Meloxicam days 1-10 / Aspirin days 5-10
干预措施: Meloxicam (Drug)
Meloxicam/Aspirin
Experimental
Meloxicam days 1-10 / Aspirin days 5-10
干预措施: Aspirin (Drug)
Aspirin
Active Comparator
Aspirin 2 days
干预措施: Aspirin (Drug)
结局指标
主要结局
Arachidonic acid induced platelet aggregation
时间窗: up to day 11 (treatment 1), up to day 3 (treatment 2)
次要结局
- Collagen-induced Platelet Aggregation(up to day 11 (treatment 1), up to day 3 (treatment 2))
- Serum Thromboxane B2 production(up to day 11 (treatment 1), up to day 3 (treatment 2))
- Assessment of tolerability on a 4-point scale(24 hours after the last Aspirin intake)
- Number of patients with clinically significant changes in vital signs(Screening, 24 hours after the last Aspirin intake)
- Adenosine diphosphate (ADP) Induced Platelet Aggregation(up to day 11 (treatment 1), up to day 3 (treatment 2))
- Number of patients with adverse events(up to 6 weeks)
- Number of patients with abnormal changes in laboratory parameters(up to day 11 (treatment 1), up to day 3 (treatment 2))
- Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)(Screening, 24 hours after the last Aspirin intake)
研究者
相似试验
已完成
3 期
Comparison effect of Naproxen and Meloxicam after fully occluded mandibular third molar surgeryExtraction of fully occluded mandibular third molar surgery.IRCT20220418054585N1Shahre-kord University of Medical Sciences30
Unknown
3 期
Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.To Investigate the Effects of Low Dose Aspirin and Low Molecular Weight Heparin in IVF Out ComeNCT01924104Dr.Vandana Bansal400
Unknown
不适用
The Effect of Low Dose Aspirin on the Pharmacokinetics of MethotrexateRheumatoid ArthritisNCT00464997Tel-Aviv Sourasky Medical Center30
招募中
3 期
The effect of low-dose aspirin on the success rate of ovulation induction in women with polycystic ovary syndromeIRCT20221112056477N1Sanandaj University of Medical Sciences120
已完成
不适用
The impact of combination thromboprophylaxis on patients with unexplained recurrent spontaneous abortions.IRCT138811073215N1vice canceller for research of Shiraz University of Medical Siences100